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Abstract: Misfolding and aggregation of -synuclein into toxic soluble oligomeric -synuclein
aggregates has been strongly correlated with the pathogenesis of Parkinson’s disease (PD).
Here, we show that two different morphologically distinct oligomeric -synuclein aggregates
are present in human post-mortem PD brain tissue and are responsible for the bulk of
-synuclein induced toxicity in brain homogenates from PD samples. Two antibody
fragments that selectively bind the different oligomeric -synuclein variants block this
-synuclein induced toxicity and are useful tools to probe how various cell models
replicate the -synuclein aggregation pattern of human PD brain. Using these reagents,
we show that mammalian cell type strongly influences -synuclein aggregation, where
neuronal cells best replicate the PD brain -synuclein aggregation profile. Overexpression
of -synuclein in the different cell lines increased protein aggregation but did not alter the
morphology of the oligomeric aggregates generated. Differentiation of the neuronal cells
into a cholinergic-like or dopaminergic-like phenotype increased the levels of oligomeric
-synuclein where the aggregates were localized in cell neurites and cell bodies.
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1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects approximately 1%
of people aged 65 and older [1]. Clinically, PD is characterized by severe motor dysfunction including
muscular rigidity, uncontrollable resting tremor and bradykinesia [1,2]. Pathologically, PD is characterized
by the selective and progressive loss of dopaminergic neurons in the substantia nigra pars compacta,
resulting in reduction of dopamine in its striatal projections and other brainstem regions. PD is also
characterized by the presence of cytoplasmic and neuritic fibrillar inclusions known as Lewy bodies
(LB) and Lewy neurites in the surviving dopaminergic neurons and other affected areas of the central
nervous system [3,4]. The presence of LBs is related with either neuronal dysfunction or neuronal
death depending on the brain region and the stage of disease [5,6]. The protein -synuclein was shown
to be a primary constituent of LBs in sporadic PD and other neurodegenerative diseases [7–11]. While
most cases of PD are sporadic, both genetic mutations in the -synuclein gene (A53T, A30P, and
E46K) and gene duplication resulting in overexpression of -synuclein have been associated with
familial forms of PD [2,12,13]. A small natively unstructured protein (14 kDa), -synuclein is expressed
mainly in brain tissues and localized in the presynaptic terminals of neurons [14]. -Synuclein can
misfold and assemble in vitro into a variety of -sheet based aggregates including small soluble
oligomeric, larger soluble protofibrillar, and fibrillar species. Environmental factors can influence
-synuclein folding as metal ions including aluminum, copper, iron, and calcium, heparin, catecholamines
such as dopamine, and pesticides such as rotenone have all been observed to facilitate stabilization of
-synuclein into its -sheet conformation [15–19]. While several morphologies of -synuclein can be
generated in vitro, increasing evidence suggest that different soluble oligomeric species rather than
mature fibril forms are responsible for neuronal dysfunction and toxicity in PD disease [20–24].
Aggregated forms of -synuclein have been shown to induce toxicity in dopaminergic neurons
in vivo [25], and different toxic mechanisms have been associated with various different aggregated
morphologies [26]. Elevated extracellular levels of oligomeric -synuclein have also been detected in
blood plasma and cerebrospinal fluid in PD patients, implicating these aggregates as important in
the etiology of PD [27–31].
While -synuclein is considered an important target for studying PD, its role in the progression
of PD pathogenesis is still largely unknown because of the complex array of different -synuclein
morphologies that exist and the lack of suitably selective tools and reagents to probe the roles of these
different species in PD models and tissues. In our lab, we have generated reagents that recognize
several distinct morphologies of -synuclein including two different oligomeric forms: the D5 antibody
fragment binds to an in vitro generated SDS-stable dimeric and tetrameric -synuclein, and the 10H antibody
fragment binds to an in vitro generated SDS-stable trimeric and hexameric -synuclein [20,21,32].
Here, we utilized the two different -synuclein oligomer specific antibody fragments (D5 and 10H) [20,21]
to identify the predominant cytotoxic species present in brain homogenates from post-mortem human
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PD brain tissue. The PD brain homogenates were shown to be substantially more cytotoxic to SH-SY5Y
cells compared to brain homogenates from age matched cognitively normal brain homogenates. The
increased cytotoxicity could be largely blocked in a concentration dependent manner by addition of D5
and/or 10H, indicating that most of the increased neuronal toxicity in human PD brain tissue samples
compared to age matched control samples is attributable to the presence of specific oligomeric -synuclein
species. We then studied how well mammalian cell lines replicate the presence of these toxic -synuclein
species. We probed for the presence of both the D5 and 10H reactive toxic -synuclein aggregates in
different mammalian cell lines expressing endogenous levels of -synuclein including non-differentiated
and differentiated human neuroblastoma cells (SH-SY5Y), Chinese hamster ovary (CHO) cells and
human embryonic kidney (HEK) cells. We also utilized HEK, CHO and SH-SY5Y cells that overexpress
-synuclein to determine whether overexpression of -synuclein can alter the protein aggregation
pathway. Undifferentiated SH-SY5Y cells have been widely used as a PD cell model; however,
this cell line can be differentiated to cholinergic-, adrenergic-, or dopaminergic- phenotypes by altering
growth conditions. Sequential exposure of SH-SY5Y cells to retinoic acid and brain derived
neurotrophic factor (BDNF) in serum-free medium yields homogeneous populations of fully
differentiated cholinergic-like and dopaminergic-like neuronal cells which are very comparable to
primary neurons [33–36]. Here, we show that the choice of cell model and differentiation state can
quite dramatically impact the -synuclein aggregation process.
2. Results and Discussion
The protein -synuclein has been strongly linked with PD and other related neurodegenerative
disorders [7,10,37]. The -synuclein protein occurs in vivo in various forms and morphologies [8,38,39],
and can interact with membranes [40–42], other proteins such as tau, p25alpha, tubulin, and transcription
factor ELK-1 [43–45], metal ions including aluminum, copper, calcium, and iron [19], and catecholamines
such as dopamine [15,46]. The various interactions can facilitate formation of different aggregate
-synuclein species. While ample evidence indicates that -synuclein plays an important role in the
pathogenesis of PD, the impact of the various conformations of -synuclein in the progression of PD is
much debated and poorly understood. Elevated levels of oligomeric -synuclein in CSF and plasma
from PD patients and in the brain samples of Lewy bodies from dementia patients has been
demonstrated [28,47]. We developed antibody fragments that selectively recognize two different toxic
oligomeric -synuclein species, D5 recognizing an in vitro generated SDS stable dimeric species [20],
and 10H recognizing an in vitro generated SDS trimeric species [21]. We showed that both of the
oligomeric aggregate species occurred in human post-mortem PD brain tissue [20,21] and CSF
samples [30]. Here, we show that the D5 and 10H reactive oligomeric -synuclein variants account for
the bulk of cytotoxicity induced by human PD brain tissue homogenates.
We utilized the human neuroblastoma cell line, SH-SY5Y, to determine cytotoxicity of homogenized
post-mortem human PD and control brain tissue samples in vitro [48]. We first quantified the levels of
both D5 and 10H reactive -synuclein aggregates in the human PD and control patient brain
homogenates using capture ELISA [49] (Figure 1). The PD brain homogenates showed significantly
higher levels of oligomeric -synuclein than the age-matched control samples, though the distribution
of D5 and 10H oligomeric species varied among PD patients. We separated the 10 different PD brain
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homogenate samples into two different PD mixes; PD-1 containing five tissue samples that have
similar levels of both D5 and 10H reactive oligomeric -synuclein (Figure 1A), and PD-2 containing
tissue samples that have substantially higher levels of 10H reactive oligomeric -synuclein compared
to D5 reactive -synuclein levels (Figure 1B). Total -synuclein levels in the control, PD-1 and PD-2
samples were all similar (Figure 1C). The different binding specificities of the D5, 10H and D10 scFvs
toward different aggregate morphologies of -synuclein are shown in Figure 1D.

Figure 1. D5 and 10H reactive -synuclein oligomers in human patient brain samples and
their cytotoxicity in SH-SY5Y cell model. (A)–(C) Relative amounts of D5 and 10H
reactive -synuclein oligomers and D10 -synuclein (reacting with total -synuclein)
present in different human PD and control brain homogenates; (D) Western blot of D5,
10H and D10 scFv binding specificity with -synuclein aggregates (adapted from [20,21]);
(E) Toxicity of homogenized brain tissue from PD-1, PD-2 and ND control brain pools
towards SH-SY5Y cells. C is a SHSY5Y cell-free control corresponding to 0% cell viability
limit. P is a healthy SHSY5Y cell control corresponding to 100% cell viability limit.
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After identifying the concentration of the different oligomeric -synuclein species in the brain
homogenate samples, we then determined the toxicity of the samples when incubated with SH-SY5Y cells.
We varied the concentration of brain tissue homogenate (1000, 500, 200, 100, 50, 20 and 0 μg/mL
total protein) incubated with the cells to determine toxicity of the PD brain homogenates relative to
control brain homogenates (Figure 1E). At the highest concentration (1000 μg/mL) both ND and
PD samples were overly toxic to the SH-SY5Y cells, and, at the lower concentrations (50, 20 and
0 μg/mL), there was minimal toxicity under the assay conditions employed. However, at total brain
protein concentrations of 500, 200 and 100 μg/mL, there was a significant difference in toxicity
observed between the PD and control samples (Figure 1E). The differences in toxicity between both
the PD-1 and PD-2 and control samples were most pronounced at a protein concentration of 200 μg/mL,
so this protein concentration was utilized for further toxicity studies.
We next determined if the increased cytotoxicity of the PD brain homogenates was attributable to
oligomeric -synuclein aggregates. When the brain homogenates were added to the SH-SY5Y cells,
we also added different concentrations of either D5 or 10H to selectively target and block different
-synuclein aggregates. For the PD-1 brain homogenate sample which contained approximately equivalent
amounts of both D5 and 10H reactive oligomeric -synuclein, cell viability was increased from 40.7%
without added scFv to 70.1% at the highest D5 concentration (Figure 2A) and 62.3% at the highest
10H concentration (Figure 2B). When both D5 and 10H scFvs were incubated together with the brain
tissue homogenates and cells, the cell viability increased to 91.1% (Figure 2C) neutralizing most of
the additional toxicity in the PD-1 sample mix relative to the control brain sample. The PD-2 brain
homogenate sample mixture contains brain tissue homogenates that contain higher levels of 10H
compared to D5 reactive oligomeric -synuclein aggregates. When cells were incubated with the PD-2
brain tissue mixture and with 10H scFv, cell viability was increased from 40.7% without added scFv to
nearly 80% (Figure 2E), but only to around 60% when co-incubated with D5 (Figure 2D). When both
D5 and 10H scFvs were incubated with the PD-2 brain tissue sample the cell viability increased
slightly more compared to treatment with 10H alone (87.2%) (Figure 2F).
With both the PD-1 and PD-2 brain mixture samples, addition of both D5 and 10H restored cell
viability to around 90% of that observed when cells were incubated with PBS buffer. Therefore, D5
and 10H reactive -synuclein aggregates are two of the primary pathological toxic -synuclein species
that are present in post-mortem human PD brain tissue. Cell models used to replicate the -synuclein
aggregation process should also be able to replicate the presence of these toxic oligomeric species. To
identify which cell models best replicate the -synuclein pathology observed in the human PD brain,
we probed several different mammalian cell lines with D5 and 10H scFvs to determine how well they
recreated the -synuclein aggregation profile found in human brain tissue. We studied how both
different cell genotypes (CHO, HEK293 and SH-SY5Y) as well as cell phenotypes (undifferentiated,
cholinergic-like and dopaminergic-like SH-SY5Y cells) affect -synuclein generation in situ. The
choice of cell line rather dramatically influences which -synuclein aggregates are generated. CHO
cells did not react with either D5 (Figure 3A-I) or 10H (Figure 3A-IV), while HEK cells reacted
strongly with D5, but only very weakly with 10H (Figure 3A-II,-V), and SH-SY5Y cells reacted
strongly with both 10H (Figure 3A-III) and D5 (Figure 3A-VI).
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Figure 2. D5 and/or 10H scFv neutralize toxicity of different human PD brain tissue
samples (PD-1 and PD-2 mix) toward SH-SY5Y cells. SH-SY5Y cells were treated with
PD patient brain homogenized supernatants (200 μg/mL) with or without different
concentrations of D5 or/and 10H scFvs (0.28, 0.55, 1.38 and 2.76 μM) for 24 h with
medium. NC is the no cell baseline value. PC (Positive control, healthy SH-SY5Y cells
treated with control brain tissue, 200 μg/mL). 2.76 + CS is the antibody control group treated
with PD patient brain homogenized supernatants (200 μg/mL) and 2.76 μM of a control
scFv. Cell viability was determined by the XTT assay. Cell viability is expressed by the
mean of three measurements ± 1 standard deviation. Statistical significance was determined
between different groups. * is p < 0.05.

(A)

Biomolecules 2015, 5

1640
Figure 3. Cont.

(B)
Figure 3. Localization of D5 and 10H reactive -synuclein aggregates in different cell
lines. (A) Localization of -synuclein aggregates in CHO, HEK and SH-SY5Y cells. Cells
were fixed with formaldehyde and probed without or with 0.2 mg/mL of D5 (red), 10H
(red) and DAPI (blue); (B) Staining of D5 and 10H reactive oligomeric -synuclein
morphologies in undifferentiated (I, IV, VII) and differentiated cholinergic-like cell (II, V,
VIII) and dopaminergic-like SH-SY5Y cells (III, VI, IX); The undifferentiated cells were
treated with anti-synaptophysin (red) (I, IV, VII), the cholinergic-like cells with anti-ChAT
(red) (II, V, VIII), and the dopaminergic-like cells with anti-TH, (red) (III, VI, IX). Cells
were fixed in 4% formaldehyde and probed without (I, II, III) or with 10H (IV, V, VI) or
with D5 (VII, VIII, IX) (green) scFv antibody fragments. Arrows indicate staining in
neurites. The scale bar equal to 50 μm.
Because dopaminergic cells are preferentially targeted in PD, we tested whether different neuronal
cell phenotypes can alter -synuclein aggregation. We generated three different neuronal cell phenotypes
(non-differentiated, cholinergic-like, and dopaminergic-like) from SH-SY5Y human neuroblastoma
cell line by sequential exposure of cells to RA and BDNF using previously described protocols [33–35].
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These protocols provide homogeneous populations of fully neuronal, differentiated cells that are very
comparable to primary neurons and exhibit characteristics of cholinergic and dopaminergic neurons,
including expression of choline acetyltransferase (ChAT), vesicular monoamine transporter (VMAT),
and tyrosine hydroxylase (TH) [33–35,50–53]. We confirmed cell phenotype by verifying expression
of neuronal differentiation markers. Cholinergic-like SH-SY5Y cells treated with RA for five days
showed high expression of ChAT (Figure 3B-II), while dopaminergic-like cells treated sequentially
with RA and BDNF showed extensive expression of TH (Figure 3B-III). After verifying that we had
cholinergic-like and dopaminergic-like neuronal cells, we then probed the different cell types for the
presence of oligomeric -synuclein with D5 and 10H scFvs. The undifferentiated, cholinergic-like and
dopaminergic-like SH-SY5Y cells all showed similar labeling with 10H (Figure 3B-IV, -V and -VI),
where the 10H reactive -synuclein aggregates were preferentially localized in the cell body in all cases
with only slight staining of neurites. In contrast, the undifferentiated SH-SY5Y cells showed D5
reactive oligomeric -synuclein aggregates present in the cytoplasm similar to 10H -synuclein aggregates
(Figure 3B-VII), while the cholinergic-like and dopaminergic-like cells also showed significant D5
reactive oligomeric -synuclein aggregates in the cell neurites and cell body (Figure 3B-VIII,-IX).
These results indicate that the D5 reactive -synuclein species are produced by all three neuronal
phenotypes in the cell body, however cholinergic-like and dopaminergic-like cells also produce D5
reactive -synuclein aggregates in the cell neurites. The 10H reactive oligomeric -synuclein species
occurs predominantly in the cell body for all three neuronal phenotypes, though they are also present in
cell neurites in both cholinergic-like and dopaminergic-like cells.
Therefore, a variety of different oligomeric -synuclein aggregates are produced by different cell
types even when -synuclein is expressed at normal levels. Our results indicate that the type and
location of the -synuclein aggregates generated depend on both cell genotype and phenotype, where
dopaminergic and cholinergic neurons preferentially generate a toxic oligomeric -synuclein species in
neurites compared to other cell types. We postulate that in healthy cells these oligomeric aggregates
are cleared through normal cellular mechanisms including proteasomal clearance and autophagy [54];
however, when these clearance processes begin to fail, toxic oligomeric -synuclein species begin to
accumulate and may spread to healthy cells through an exosomal mediated mechanism [26,55,56].
Since overexpression of -synuclein has been extensively used in cell and animal models of PD, we
also studied how overexpression of -synuclein affects the aggregation state of -synuclein.
We induced -synuclein overexpression in CHO, HEK, and SH-SY5Y cells by transfection with
the WTsynEGFP gene so excess expression of -synuclein could be readily verified by fluorescence.
We then investigated whether there was a change in oligomeric -synuclein aggregation induced by
overexpression. Overexpression of -synuclein in CHO cells still did not result in the presence of D5
(Figure 4A) or 10H (Figure 4D) reactive -synuclein aggregates similar to what we observed when the
cells expressed endogenous levels of -synuclein (Figure 3A-I,-IV). Similarly with HEK cells,
overexpression of -synuclein led to the presence of both D5 (Figure 4B) and 10H (Figure 4E) reactive
-synuclein aggregates with much higher presence of D5 reactive aggregates than 10H again similar
to results observed with endogenous expression (Figure 3A-II,-V). Finally, with undifferentiated
SH-SY5Y cells, 10H and D5 reactive -synuclein aggregates were observed (Figure 4C,F), again
similar to the results observed with endogenous levels of -synuclein expression (Figure 3A-III,-VI).
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Figure 4. Localization of D5 and 10H reactive -synuclein aggregates in CHO, HEK and
SH-SY5Y cells overexpressing -synuclein. Cells were seeded in 6-well plates with a density
of 105 cells/well and treated with 2:1 transfected reagent and wt-synuclein-EGFP (green).
After 72 h, the cells were fixed with formaldehyde and probed without or with D5 or 10H
scFv antibody fragments (red). Arrows indicate co-localization. The scale bar equal to 50 μm.
We quantified the levels of total -synuclein and the D5, 10H reactive oligomeric -synuclein in the
different cell lines expressing both endogenous and overexpressed levels of -synuclein by ELISA
(Figure 5). Overexpression of -synuclein in CHO cells did not result in a significant increase in D5 or
10H reactive -synuclein aggregates in the supernatant or cell lysate although the total -synuclein
levels (D10) were substantially higher in supernatant and lysate. Overexpression of -synuclein
in HEK cells only very modestly increased levels of D5 and 10H reactive oligomeric -synuclein
in both supernatant and lysate cells (p < 0.05) (Figure 5). However, overexpression of -synuclein in
undifferentiated SH-SH5Y cells significantly increased levels of D5 reactive oligomeric -synuclein in
both supernatant and cell lysates, while 10H levels reactive -synuclein levels did not increase substantially
with -synuclein overexpression (Figure 5). Therefore, overexpression of -synuclein does not induce
formation of toxic oligomeric -synuclein variants in cell lines that do not naturally produce them;
however, the levels of different -synuclein species generated may vary with expression level. These
results indicate that in PD models, choice of cell type affects the -synuclein aggregation process and
cytotoxicity much more than expression levels.
In summary, oligomeric -synuclein aggregates represent the primary cytotoxic -synuclein species
present in post-mortem human PD brain tissue and this toxicity can be largely eliminated by targeting
two different morphological species of -synuclein aggregate using the D5 and 10H scFvs. We further
show that when trying to replicate this toxic -synuclein pathology in PD models, both cell genotype
and phenotype strongly influence the aggregation state of -synuclein, though expression levels do not.
Differentiation of SH-SY5Y cells into cholinergic and dopaminergic phenotypes gave distinct -synuclein
aggregation patterns that were similar to those observed with rat primary neurons, suggesting that
differentiated neurons may be a reasonable cell model to study -synuclein toxicity in PD.
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Figure 5. The levels of total -synuclein (D10) and D5 and 10H reactive oligomeric
-synuclein aggregates in cell supernatant and lysate with endogenous and overexpressed
levels of -synuclein. Levels of the different -synuclein species were determined by
capture ELISA (D5 and 10H) or by indirect ELISA (D10) [49]. Cells (105/mL) were
seeded in a six well plate and transfected with or without wt-synuclein-EGFP. -Synuclein
levels are expressed as the mean value of three measurements ± standard deviation.
Statistical significance was determined at transfected cells vs. normal cells. * is p < 0.05.
3. Experimental Section
3.1. Materials
Cell Culture
HEK293 Cells. Human embryonic kidney (HEK293) cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM), from Invitrogen, supplemented with 10% fetal bovine serum (FBS, Sigma,
St Louis, MO, USA), 1% penicillin/streptomycin and 2% L-glutamine (Life Technologies, New York,
NY, USA) at 37 °C, in a 5% CO2 atmosphere. HEK293 cells were generous gifts from Nick Webster
(Wadsworth Center, Albany, NY, USA).
CHO Cells. Chinese hamster ovary cells (CHO) cells were cultured in the same medium as above,
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-glutamine (Life
Technologies) and grown at 37 °C, in a 5% CO2 atmosphere. CHO cells [57] were generous gifts from
Dennis Selkoe (Harvard Medical School).
SH-SY5Y Cells. SH-SY5Y human neuroblastoma cell line cells were maintained in culture flasks in
medium containing (v/v) minimal essential medium (MEM), (v/v) Ham’s modification of F-12,
10% fetal bovine serum (FBS, Sigma), 1% non-essential amino acid, and 1% antibiotic-antimycotic (Life
Technologies) and grown in a 5% CO2 atmosphere at 37 °C. The SH-SY5Y cell line was purchased from
ATCC (Vienna, VA, USA), minimal essential medium (MEM) and Ham’s modification F-12 were obtained
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from Irvine Scientific (Santa Ana, CA, USA). Non-essential amino acids and antibiotic-antimycotic 100x
were obtained from Invitrogen (Carlsbad, CA, USA). All chemicals were obtained from Sigma-Aldrich
(St. Louis, MO, USA) unless otherwise indicated.
Differentiated SH-SY5Y Cells. SH-SY5Y cells were harvested from flasks and plated in 6-well
polystyrene plates (Corning Inc., Corning, NY, USA) coated previously with 0.5 mg/mL collagen with
density of 105 cells per well. The cells were differentiated to cholinergic-like neuronal cells by addition
of 10 μM retinoic acid (Sigma-Aldrich) in media with serum for 4 days at 37 °C. After 4 days in the
presence of RA, cells were differentiated to dopaminergic-like neuronal cells by incubating with 50 ng/mL
of brain-derived neurotrophic factor (BDNF) (PeproTech, Rocky Hill, NJ, USA) in media without
serum for 7 days at 37 °C as described [33–36].
Transient Transfection of SH-SY5Y, CHO and HEK Cells. Transient transfection of cells was
performed using FuGENE HD Transfection Reagent according to the manufacturer’s protocol
(Promega, Madison, WI, USA) with slight modification [13]. Briefly, SH-SY5Y cells (105 cells/well)
were seeded in 1 mL of growth medium in 6 well plates for 1 or 2 days before transfection (50%–70%
confluence). A transfection mixture consisting of wild type -synuclein/EGFP (WTsynEGFP) fusion
protein plasmid DNA (Clontech, Palo Alto, CA, USA) and Fugene reagent (1:2 v/v) in serum-free media
was pre-incubated in the dark for 15 min. at room temperature before addition to the cells. Cell culture
media was removed, and after the transfection mixture (500 L) was added to each well, the culture was
incubated for 1 h at 37 °C, followed by addition of complete media with serum (500 L). The cultures
were incubated and grown in a 5% CO2 atmosphere at 37 °C for 72 h. The cells were then probed with
D5 or 10H as described above.
3.2. Purification of D5, 10H and D10 Fragments and Western Blot
The D5 and 10H single chain antibody fragments (scFv) were purified using a protein A sepharose
column as described previously [20,21]. Briefly, the supernatant and periplasmic fractions from a 1 L
culture were combined, passed through a 0.2 m filter (Whatman, Clifton, NJ, USA), and then concentrated
in a tangential flow filter (Millipore, Billerica, MA, USA) using a 10 kDa filter membrane (Millipore).
Concentrated samples were applied to a protein A-Sepharose column (GE healthcare, NJ, USA) which
was equilibrated in PBS 1x, pH 7.4, at 4 °C. After washing the column in the same buffer, bound
antibody fragments were eluted from the column with 0.2 M glycine, pH 3. Fractions containing antibody
fragments were pooled, adjusted to neutral pH, dialyzed into PBS and stored at 20 °C. The purity of
the antibody fragments was estimated by electrophoresis on 12% (w/v) SDS-polyacrylamide gels and
Western Blot (method see Emadi et al., 2007) [20,21].
3.3. Preparation of Brain Tissue Homogenates
Post-mortem brain tissue samples from pathologically verified age-matched non-diseased (ND) and
Parkinson’s disease (PD) patients were generously provided by Dr. Thomas Beach (Civin Laboratory
for Neuropathology, Sun Health Research Institute, Sun City, AZ, USA) (Table 1). The middle
temporal gyrus (MTG) of ten different PD samples and five age matched cognitively normal ND
samples were separately homogenized in 0.1 M Tris/Lysis buffer (pH 7.4) with protease inhibitor
(Pierce), centrifuged and combined as PD and ND samples, respectively. The PD samples (Table 1)
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were split into two groups of five samples each based on the relative amounts of D5 and 10H reactive
oligomeric -synuclein aggregates present in each sample where PD-1 group contained samples with
relatively similar amounts of D5 and 10H reactive -synuclein aggregates and PD-2 group contained
samples with predominantly 10H reactive -synuclein aggregates [49].
Table 1. Human Brain Samples for Parkinson’s Disease PD-1, PD-2 and ND.
Sample

Gender

Age

PD-1

M
F
M
F
M

85
73
75
74
77

F
M

78
72

F

91

PD-2

ND

F

82

M

70

M

79

M

65

F

87

M
F

89
83

3.4. Incubation of Human Brain Tissue Homogenates with SH-SY5Y Cells
The toxicity of the brain tissue samples towards human neuroblastoma SH-SY5Y cells was
measured using an XTT assay [48]. SH-SY5Y cell line were cultured at 37 °C in a humidified
atmosphere with 5% CO2, in a HEPES (20 mM)-buffered RPMI 1640 cell culture medium supplemented
with 2 mM L-glutamine, antibiotic/antimycotic mixture (1%) and 10% fetal bovine serum (FBS). Cells
were treated with PD patient brain homogenized supernatants (100 μg/mL) with or without added D5 or
10H scFv (0, 0.28, 0.55, 1.38 and 2.76 M of scFv in final medium) for 24 h with above medium. ND
brain homogenized supernatants was used as control sample to show the toxicity background. Cell
viability was determined by the XTT assay. The cells incubated in 96-well flat-bottom plates for
the cell viability assessment were 2 × 104 cells/well. A freshly prepared XTT-PMS labeling mixture
(50 L) was added to the cell culture and incubated for 3–4 h. The absorbance was measured at 450 nm
and 570 nm in an automated microplate reader. All sample values were normalized to a mixture
containing five control patient samples (ND).
3.5. Immunofluorescent Staining
Cells were fixed in 4% formaldehyde in PBS at room temperature for 15 min. Then cells were
treated with 0.2% Triton 100 at room temperature for 15 min., washed three times with PBS and blocked
for 1 h with PBS containing 5% goat serum. The cells were incubated overnight (ON) with 0.3 mg/mL
of D5 and/or 10H scFv. The primary antibodies (mouse anti-c-Myc (Sigma), anti-Synaptophysin (Santa
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Cruz Biotechnology, Dallas, TX, USA), anti-choline acetyltransferase (Santa Cruz Biotechnology) and
anti-tyrosine hydroxylase, all at a 1/100 dilution) were then applied to the cells, which were incubated
for 2 h at room temperature. The cells were washed 3 times with PBS and incubated with 1/1000
dilution of the secondary antibodies (goat anti-mouse IgG Alexa Fluor 488 and goat anti-rabbit Alexa
Fluor 594, Life Technologies) or DAPI (Sigma) for 1 h at room temperature. The images were taken
with a fluorescent microscope (Observer D1, Zeiss).
3.6. Capture ELISA
High binding polystyrene microtiter plates were coated with 0.3 μg/mL of D5 or 10H scFv in
carbonate-bicarbonate, pH 9.6 at 4 °C for overnight. Non-specific binding was blocked by incubating
with 2% PBS-milk at 37 °C for 1 h. The plates were then incubated with an aliquot of supernatant or
cell lysate from untransfected and transfected SHSY5Y, CHO and HEK cells, for 2 h at 37 °C. After
washing, an aliquot of 1010 titer units of PEG precipitated D10 phage in 100 μL of 2% PBS-milk was
added to each well and incubated for 90 min at room temperature. Bound phages were detected after 1
h incubation with a 1:2000 dilution of avidin- horseradish peroxidase (HRP) conjugate. A 100 μL
aliquot of the HRP substrate 3.3'.5.5'-tetramethylbenzidine (TMB, Sigma) was added and the reaction
was stopped after 20 min with 2 M H2SO4. The activity was determined by subtracting OD650 from
OD450 using a Wallac 1420 plate reader (Perkin Elmer, Waltham, MA, USA) and comparing absorbance
between control well (without D10 phage) to the sample well (with D10 phage) where the control
value was normalized to 1.
To measure oligomer content in the brain tissue the wells were coated with 0.3 μg /mL of 10H or
D5 scFv for 1 h at 37 °C. The wells were then blocked for 1 h at 37 °C with 2% milk. Brain tissue was
added at a concentration of 100 ug/mL for 1 h at 37 °C followed by the detection antibody, biotinylated
D10 phage, at 1/1000 dilution. Next, a 1/1000 dilution of avidin-HRP (Sigma-Aldrich) was added to
wells and binding detected using the SuperSignal ELISA Femto Maximum Sensitivity Substrate kit
(Thermo Scientific, Waltham, MA, USA). Signals were measured using a Wallac Victor2 microplate
reader after 1 and 20 min. Signals were compared to the PBS controls (PBS added in place of brain
tissue) and then to the NDs.
3.7. Statistical Analysis
All the experiments were performed in triplicate unless otherwise stated. The data in the text and
figures are expressed as mean ± 1 SEM. Statistical comparisons between groups were assayed using
t test. One way ANOVA was used to test for significance. P-values less than 0.05 were considered
significant. In the ELISAs, the PDs were normalized relative to the NDs. All the analyses were
performed using SPSS for Windows version 13.0 (SPSS Software, IBM, Hong Kong, China).
4. Conclusions
In summary, oligomeric -synuclein aggregates represent the primary cytotoxic -synuclein species
present in post-mortem human PD brain tissue and this toxicity can be largely eliminated by targeting
two different morphological species of -synuclein aggregate using the D5 and 10H scFvs. We further
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show that, when trying to replicate this toxic -synuclein pathology in PD models, both cell genotype
and phenotype strongly influence the aggregation state of -synuclein, though expression levels do not.
Differentiation of SH-SY5Y cells into cholinergic and dopaminergic phenotypes gave distinct -synuclein
aggregation patterns that were similar to those observed with rat primary neurons, suggesting that
differentiated neurons may be a reasonable cell model to study -synuclein toxicity in PD.
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